129 related articles for article (PubMed ID: 32005236)
1. Correction to: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2020 Feb; 18(1):29. PubMed ID: 32005236
[TBL] [Abstract][Full Text] [Related]
2. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
3. Correction: Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.
Kang MH; Jeong KJ; Kim WY; Lee HJ; Gong G; Suh N; Győrffy B; Kim S; Jeong SY; Mills GB; Park YY
Oncogene; 2019 May; 38(22):4427-4428. PubMed ID: 30718918
[TBL] [Abstract][Full Text] [Related]
4. [Corrigendum] Inhibition of MDA-MB-231 breast cancer cell migration and invasion activity by andrographolide via suppression of nuclear factor-κB-dependent matrix metalloproteinase-9 expression.
Zhai Z; Qu X; Li H; Ouyang Z; Yan W; Liu G; Liu X; Fan Q; Tang T; Dai K; Qin A
Mol Med Rep; 2019 Mar; 19(3):1979. PubMed ID: 30628678
[TBL] [Abstract][Full Text] [Related]
5. EGFR inhibition in NSCLC: the emerging role of cetuximab.
Herbst RS
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
[TBL] [Abstract][Full Text] [Related]
6. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
[TBL] [Abstract][Full Text] [Related]
7. Author Correction: Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling.
Usman MW; Gao J; Zheng T; Rui C; Li T; Bian X; Cheng H; Liu P; Luo F
Cell Death Dis; 2019 Jun; 10(7):501. PubMed ID: 31235854
[TBL] [Abstract][Full Text] [Related]
8. Erratum.
Expert Rev Hematol; 2015 Oct; 8(5):699. PubMed ID: 26343894
[TBL] [Abstract][Full Text] [Related]
9. [Corrigendum] miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1.
Li Y; Zhao L; Li N; Miao Y; Zhou H; Jia L
Oncol Rep; 2019 May; 41(5):3148. PubMed ID: 30896876
[TBL] [Abstract][Full Text] [Related]
10. [Corrigendum] Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK‑mediated DR5 regulation in colorectal cancer.
Kim SL; Min IS; Park YR; Lee ST; Kim SW
Int J Oncol; 2019 May; 54(5):1897. PubMed ID: 30864690
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Cui S; Jiang L
Tumour Biol; 2017 May; 39(5):1010428317705340. PubMed ID: 28468578
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
14. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
15. [Corrigendum] AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
Choi YJ; Kim JH; Rho JK; Kim JS; Choi CM; Kim WS; Son J; Lee JC
Oncol Rep; 2019 Jan; 41(1):719. PubMed ID: 30542697
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
[TBL] [Abstract][Full Text] [Related]
17. Correction to: Age Patterns in Risk Taking Across the World.
Duell N; Steinberg L; Icenogle G; Chein J; Chaudhary N; Di Giunta L; Dodge KA; Fanti KA; Lansford JE; Oburu P; Pastorelli C; Skinner AT; Sorbring E; Tapanya S; Tirado LMU; Alampay LP; Al-Hassan SM; Takash HMS; Bacchini D; Chang L
J Youth Adolesc; 2019 Apr; 48(4):835-836. PubMed ID: 30820728
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV
J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
